Weekly Digest – July 2026 Weekly Digest – July 2026 28 July 2026: AstraZeneca receives CDSCO approval for Enhertu followed by THP for adults with HER2-positive stage II or III early Breast cancer AstraZeneca Pharma India announced that the Central […]
Weekly Digest – July 2026 Weekly Digest – July 2026 29 July 2026: AbbVie announces availability of ELAHERE in Singapore for the treatment of platinum-resistant Ovarian cancer AbbVie announced the availability of ELAHERE, the first folate receptor alpha-targeted antibody-drug conjugate, […]
Weekly Digest – July 2026 Weekly Digest – July 2026 29 July 2026: ImmunityBio receives UAE Marketing Authorization for ANKTIVA in BCG-unresponsive NMIBC (CIS and papillary disease) and mNSCLC ImmunityBio announced that the United Arab Emirates has granted marketing authorization […]
Weekly Digest – July 2026 Weekly Digest – July 2026 28 July 2026: DualityBio and BioNTech’s B7-H3 ADC DB-1311 granted China NMPA BTD for metastatic castration-resistant Prostate cancer DualityBio and BioNTech announced that China’s NMPA has granted Breakthrough Therapy Designation […]
Weekly Digest – July 2026 Weekly Digest – July 2026 24 July 2026: Gilead announces CHMP recommendation for Trodelvy + Keytruda in 1L PD-(L)1+ mTNBC Gilead announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has […]
Weekly Digest – July 2026 Weekly Digest – July 2026 24 July 2026: EU CHMP recommends Enhertu plus Pertuzumab for 1L HER2 metastatic Breast cancer AstraZeneca and Daiichi Sankyo announced that the European Medicines Agency’s Committee for Medicinal Products for […]
